Moore, John P

Publications

Sort by

Co-Author Network

selected publications

Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Retrovirology. 2023 Academic Article GET IT
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell reports. Medicine. 2023 Academic Article GET IT
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Research square. 2023 Article GET IT
Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons. American journal of obstetrics & gynecology MFM. 2022 Academic Article GET IT
Times cited: 2
Asthma 17q21 polymorphism associates with decreased risk of COVID-19 in children. Pediatric pulmonology. 2022 Letter GET IT
Times cited: 2
Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. iScience. 2022 Academic Article GET IT
Times cited: 662
Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 2
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of virology. 2022 Review GET IT
Times cited: 4
Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. NPJ vaccines. 2021 Article GET IT
Times cited: 1
The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of virology. 2021 Academic Article GET IT
Times cited: 7
Beta testing the monkey model. Nature immunology. 2021 Comment GET IT
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Science advances. 2021 Academic Article GET IT
Times cited: 42
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS pathogens. 2021 Academic Article GET IT
Times cited: 6
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American journal of hematology. 2021 Letter GET IT
Times cited: 22
Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 6
Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. Journal of virology. 2021 Academic Article GET IT
Times cited: 3
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nature communications. 2021 Academic Article GET IT
Times cited: 9
Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging infectious diseases. 2021 Academic Article GET IT
Times cited: 33
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathogens & immunity. 2021 Academic Article GET IT
Times cited: 6
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. medRxiv : the preprint server for health sciences. 2021 Article GET IT
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. The Journal of clinical endocrinology and metabolism. 2021 Academic Article GET IT
Times cited: 16
Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA. 2021 Academic Article GET IT
Times cited: 44
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell reports. 2021 Academic Article GET IT
Times cited: 19
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science advances. 2021 Review GET IT
Times cited: 68
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv : the preprint server for biology. 2021 Article GET IT
Virus vaccines: proteins prefer prolines. Cell host & microbe. 2021 Review GET IT
Times cited: 39
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA. 2021 Academic Article GET IT
Times cited: 137
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 2311
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosensors & bioelectronics. 2021 Academic Article GET IT
Times cited: 14
High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. eLife. 2021 Academic Article GET IT
Times cited: 5
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. 2020 GET IT
Times cited: 18
Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of virology. 2020 Academic Article GET IT
Times cited: 11
Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. medRxiv : the preprint server for health sciences. 2020 Article GET IT
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 33
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. Journal of virology. 2020 Review GET IT
Times cited: 59
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 30
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife. 2020 Academic Article GET IT
Times cited: 69
Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. eLife. 2020 Review GET IT
Times cited: 57
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nature medicine. 2020 Academic Article GET IT
Times cited: 79
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. Cell host & microbe. 2020 Review GET IT
Times cited: 32
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Journal of virology. 2020 Academic Article GET IT
Times cited: 19
SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers. Journal of virology. 2019 Academic Article GET IT
Times cited: 3
Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. Journal of virology. 2019 Academic Article GET IT
Times cited: 11
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature communications. 2019 Academic Article GET IT
Times cited: 96
Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell host & microbe. 2019 Academic Article GET IT
Times cited: 24
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature communications. 2019 Academic Article GET IT
Times cited: 79
Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells. PloS one. 2019 Academic Article GET IT
Times cited: 9
Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. Nature communications. 2019 Academic Article GET IT
Times cited: 17
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. Journal of pharmaceutical sciences. 2019 Academic Article GET IT
Times cited: 12
Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. The Journal of biological chemistry. 2019 Academic Article GET IT
Times cited: 13
Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of virology. 2019 Academic Article GET IT
Times cited: 50
Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell reports. 2018 Academic Article GET IT
Times cited: 80
Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. Journal of virology. 2018 Academic Article GET IT
Times cited: 27
Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 21
Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. Journal of virology. 2018 Academic Article GET IT
Times cited: 51
Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 71
Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Journal of proteome research. 2018 Academic Article GET IT
Times cited: 19
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnology and bioengineering. 2017 Academic Article GET IT
Times cited: 52
Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 28
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 18
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. The Journal of experimental medicine. 2017 Academic Article GET IT
Times cited: 105
Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell reports. 2017 Academic Article GET IT
Times cited: 115
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PloS one. 2017 Academic Article GET IT
Times cited: 13
Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature. 2017 Academic Article GET IT
Times cited: 157
Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 37
Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Journal of virology. 2017 Academic Article GET IT
Times cited: 23
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 66
Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. Proteins. 2017 Academic Article GET IT
Times cited: 5
Publishing: Journals, do your own formatting. Nature. 2017 Letter GET IT
Times cited: 5
Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. Journal of virology. 2017 Academic Article GET IT
Times cited: 54
Native-like Env trimers as a platform for HIV-1 vaccine design. Immunological reviews. 2017 Review GET IT
Times cited: 171
Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell reports. 2016 Academic Article GET IT
Times cited: 118
HIV's Achilles' Heel. Scientific American. 2016 Academic Article GET IT
Times cited: 6
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature microbiology. 2016 Academic Article GET IT
Times cited: 104
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 204
Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 101
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 192
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell reports. 2016 Academic Article GET IT
Times cited: 192
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends in immunology. 2016 Review GET IT
Times cited: 77
Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins. Journal of virology. 2015 Academic Article GET IT
Times cited: 26
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell. 2015 Academic Article GET IT
Times cited: 249
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity. 2015 Academic Article GET IT
Times cited: 163
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 36
Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Journal of virology. 2015 Academic Article GET IT
Times cited: 28
Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology. 2015 Academic Article GET IT
Times cited: 34
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology. 2015 Academic Article GET IT
Times cited: 123
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature communications. 2015 Academic Article GET IT
Times cited: 65
Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proceedings of the National Academy of Sciences of the United States of America. 2015 Academic Article GET IT
Times cited: 102
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of virology. 2015 Academic Article GET IT
Times cited: 67
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of virology. 2015 Academic Article GET IT
Times cited: 106
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS research and human retroviruses. 2015 Academic Article GET IT
Times cited: 10
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 391
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015 Academic Article GET IT
Times cited: 200
Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell reports. 2015 Academic Article GET IT
Times cited: 101
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 84
What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. Journal of virology. 2015 Academic Article GET IT
Times cited: 21
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature communications. 2015 Academic Article GET IT
Times cited: 100
A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. Journal of virology. 2015 Academic Article GET IT
Times cited: 192
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 244
HIV: A stamp on the envelope. Nature. 2014 Comment GET IT
Times cited: 24
Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell. 2014 Academic Article GET IT
Times cited: 141
Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. European journal of immunology. 2014 Academic Article GET IT
Times cited: 42
Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. Journal of virology. 2014 Academic Article GET IT
Times cited: 52
CD4-induced activation in a soluble HIV-1 Env trimer. Structure (London, England : 1993). 2014 Academic Article GET IT
Times cited: 100
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014 Academic Article GET IT
Times cited: 124
Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology. 2014 Academic Article GET IT
Times cited: 45
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014 Academic Article GET IT
Times cited: 283
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014 Academic Article GET IT
Times cited: 268
Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens. Journal of immunology (Baltimore, Md. : 1950). 2014 Academic Article GET IT
Times cited: 3
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 Academic Article GET IT
Times cited: 550
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. Journal of pharmaceutical sciences. 2014 Academic Article GET IT
Times cited: 16
Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. The Journal of antimicrobial chemotherapy. 2013 Academic Article GET IT
Times cited: 12
Another HIV vaccine failure: where to next?. Nature medicine. 2013 Comment GET IT
Times cited: 15
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 561
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 682
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 151
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS pathogens. 2013 Academic Article GET IT
Times cited: 661
Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. Journal of virology. 2013 Academic Article GET IT
Times cited: 73
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. Journal of virology. 2013 Academic Article GET IT
Times cited: 64
Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. PloS one. 2013 Academic Article GET IT
Times cited: 7
An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PloS one. 2013 Academic Article GET IT
Times cited: 5
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature structural & molecular biology. 2013 Academic Article GET IT
Times cited: 272
Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PloS one. 2013 Academic Article GET IT
Times cited: 14
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS pathogens. 2013 Academic Article GET IT
Times cited: 236
Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. Journal of virology. 2013 Academic Article GET IT
Times cited: 29
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 208
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. Journal of virology. 2012 Academic Article GET IT
Times cited: 62
Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 29
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. The Journal of antimicrobial chemotherapy. 2012 Academic Article GET IT
Times cited: 54
Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. The Journal of antimicrobial chemotherapy. 2012 Academic Article GET IT
Times cited: 29
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 23
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. Retrovirology. 2012 Review GET IT
Times cited: 12
Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. Journal of virology. 2012 Academic Article GET IT
Times cited: 56
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 42
Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 38
Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array. Journal of the American Chemical Society. 2012 Academic Article GET IT
Times cited: 56
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology. 2012 Academic Article GET IT
Times cited: 14
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology. 2012 Academic Article GET IT
Times cited: 31
HIV-1 Env antibodies: are we in a bind or going blind?. Nature medicine. 2012 Letter GET IT
Times cited: 7
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrobial agents and chemotherapy. 2012 Academic Article GET IT
Times cited: 59
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrobial agents and chemotherapy. 2012 Academic Article GET IT
Times cited: 8
Animal models for microbicide studies. Current HIV research. 2012 Review GET IT
Times cited: 53
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. Journal of virology. 2011 Academic Article GET IT
Times cited: 37
SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PloS one. 2011 Academic Article GET IT
Times cited: 12
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology. 2011 Academic Article GET IT
Times cited: 16
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (New York, N.Y.). 2011 Academic Article GET IT
Times cited: 573
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. Journal of controlled release : official journal of the Controlled Release Society. 2011 Academic Article GET IT
Times cited: 49
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS research and human retroviruses. 2011 Academic Article GET IT
Times cited: 27
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 133
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology. 2011 Academic Article GET IT
Times cited: 24
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 222
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. Journal of virology. 2011 Academic Article GET IT
Times cited: 52
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS research and human retroviruses. 2011 Review GET IT
Times cited: 60
A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. The Journal of biological chemistry. 2011 Academic Article GET IT
Times cited: 15
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology. 2011 Academic Article GET IT
Times cited: 21
Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. The Journal of biological chemistry. 2010 Academic Article GET IT
Times cited: 22
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. The Journal of infectious diseases. 2010 Academic Article GET IT
Times cited: 125
Misconduct: don't penalize the honest majority of scientists. Nature. 2010 Letter GET IT
Times cited: 1
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS research and human retroviruses. 2010 Academic Article GET IT
Times cited: 93
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology. 2010 Academic Article GET IT
Times cited: 62
Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion. Journal of virology. 2010 Academic Article GET IT
Times cited: 16
Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat. American journal of respiratory cell and molecular biology. 2009 Academic Article GET IT
Times cited: 4
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 216
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS pathogens. 2009 Academic Article GET IT
Times cited: 62
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine. 2009 Academic Article GET IT
Times cited: 53
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology. 2009 Academic Article GET IT
Times cited: 45
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry. 2009 Academic Article GET IT
Times cited: 50
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology. 2009 Academic Article GET IT
Times cited: 36
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 180
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 86
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Current opinion in HIV and AIDS. 2009 Review GET IT
Times cited: 80
Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology. 2009 Academic Article GET IT
Times cited: 29
The use of nonhuman primate models in HIV vaccine development. PLoS medicine. 2008 Academic Article GET IT
Times cited: 86
Whither or wither microbicides?. Science (New York, N.Y.). 2008 Academic Article GET IT
Times cited: 117
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 40
Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology. 2008 Academic Article GET IT
Times cited: 51
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nature medicine. 2008 Academic Article GET IT
Times cited: 233
AIDS/HIV. A STEP into darkness or light?. Science (New York, N.Y.). 2008 Academic Article GET IT
Times cited: 44
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annual review of medicine. 2008 Review GET IT
Times cited: 159
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology. 2007 Academic Article GET IT
Times cited: 22
HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex. Cell host & microbe. 2007 Review GET IT
Times cited: 13
Speaking out about U.S. science output. Science (New York, N.Y.). 2007 Letter GET IT
Times cited: 1
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS pathogens. 2007 Academic Article GET IT
Times cited: 78
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS pathogens. 2007 Academic Article GET IT
Times cited: 42
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. AIDS research and human retroviruses. 2007 Academic Article GET IT
Times cited: 24
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology. 2007 Academic Article GET IT
Times cited: 46
Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology. 2007 Academic Article GET IT
Times cited: 32
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry. 2007 Academic Article GET IT
Times cited: 45
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology. 2007 Academic Article GET IT
Times cited: 37
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology. 2006 Academic Article GET IT
Times cited: 153
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology. 2006 Academic Article GET IT
Times cited: 86
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology. 2006 Academic Article GET IT
Times cited: 37
A plea for justice for jailed medical workers. Science (New York, N.Y.). 2006 Letter GET IT
Times cited: 4
Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS medicine. 2006 Review GET IT
Times cited: 62
Construction and characterization of soluble, cleaved, and stabilized trimeric Env proteins based on HIV type 1 Env subtype A. AIDS research and human retroviruses. 2006 Academic Article GET IT
Times cited: 23
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology. 2006 Academic Article GET IT
Times cited: 19
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 182
The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein expression and purification. 2006 Academic Article GET IT
Times cited: 40
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology. 2006 Academic Article GET IT
Times cited: 113
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nature medicine. 2005 Academic Article GET IT
Times cited: 83
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 2005 Academic Article GET IT
Times cited: 276
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (New York, N.Y.). 2005 Academic Article GET IT
Times cited: 64
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. Journal of virology. 2005 Academic Article GET IT
Times cited: 47
Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology. 2005 Academic Article GET IT
Times cited: 33
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology. 2005 Academic Article GET IT
Times cited: 142
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology. 2005 Academic Article GET IT
Times cited: 66
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of virology. 2005 Academic Article GET IT
Times cited: 108
Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. Virology. 2005 Academic Article GET IT
Times cited: 5
Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells. The Journal of infectious diseases. 2005 Letter GET IT
Times cited: 1
Online submission makes authors do all the work. Nature. 2005 Letter GET IT
Times cited: 3
V3: HIV's switch-hitter. AIDS research and human retroviruses. 2005 Review GET IT
Times cited: 251
Topical microbicides become topical. The New England journal of medicine. 2005 Academic Article GET IT
Times cited: 33
Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology. 2004 Academic Article GET IT
Times cited: 50
Urgently needed: a filter for the HIV-1 vaccine pipeline. Nature medicine. 2004 Academic Article GET IT
Times cited: 39
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS research and human retroviruses. 2004 Academic Article GET IT
Times cited: 21
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?. Virology. 2004 Review GET IT
Times cited: 72
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. The Journal of experimental medicine. 2004 Academic Article GET IT
Times cited: 207
The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. Journal of virology. 2004 Academic Article GET IT
Times cited: 44
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology. 2004 Academic Article GET IT
Times cited: 70
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology. 2004 Academic Article GET IT
Times cited: 32
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. Journal of virology. 2004 Academic Article GET IT
Times cited: 189
HIV vaccine design and the neutralizing antibody problem. Nature immunology. 2004 Academic Article GET IT
Times cited: 681
HIV-1 entry inhibitor entrances. Trends in pharmacological sciences. 2004 Review GET IT
Times cited: 13
HIV denialists will exploit any journal's tolerance. Nature. 2004 Letter GET IT
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrobial agents and chemotherapy. 2004 Academic Article GET IT
Times cited: 122
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (New York, N.Y.). 2004 Academic Article GET IT
Times cited: 111
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS research and human retroviruses. 2004 Review GET IT
Times cited: 393
Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. Journal of virology. 2003 Academic Article GET IT
Times cited: 36
Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood. 2003 Academic Article GET IT
Times cited: 137
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. The Journal of experimental medicine. 2003 Academic Article GET IT
Times cited: 142
Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?. The Journal of antimicrobial chemotherapy. 2003 Review GET IT
Times cited: 25
Inhibiting sexual transmission of HIV-1 infection. Nature reviews. Microbiology. 2003 Review GET IT
Times cited: 445
The entry of entry inhibitors: a fusion of science and medicine. Proceedings of the National Academy of Sciences of the United States of America. 2003 Academic Article GET IT
Times cited: 262
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. Journal of virology. 2003 Academic Article GET IT
Times cited: 206
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. Journal of virology. 2003 Academic Article GET IT
Times cited: 62
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood. 2003 Academic Article GET IT
Times cited: 102
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. Journal of virology. 2003 Academic Article GET IT
Times cited: 142
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS research and human retroviruses. 2003 Academic Article GET IT
Times cited: 48
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature medicine. 2003 Academic Article GET IT
Times cited: 434
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. Journal of virology. 2003 Academic Article GET IT
Times cited: 56
Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. Journal of virology. 2003 Academic Article GET IT
Times cited: 66
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of virology. 2002 Academic Article GET IT
Times cited: 368
Inhibition of HIV-1 replication in alveolar macrophages by adenovirus gene transfer vectors. American journal of respiratory cell and molecular biology. 2002 Academic Article GET IT
Times cited: 2
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. Journal of virology. 2002 Academic Article GET IT
Times cited: 144
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Journal of virology. 2002 Academic Article GET IT
Times cited: 507
HIV tropism and CD4+ T-cell depletion. Nature medicine. 2002 Letter GET IT
Times cited: 22
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. Journal of virology. 2002 Academic Article GET IT
Times cited: 189
AIDS vaccine models: challenging challenge viruses. Nature medicine. 2002 Academic Article GET IT
Times cited: 171
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. Journal of virology. 2002 Academic Article GET IT
Times cited: 118
Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. Journal of virology. 2002 Academic Article GET IT
Times cited: 42
AIDS vaccines: on the trail of two trials. Nature. 2002 Academic Article GET IT
Times cited: 7
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proceedings of the National Academy of Sciences of the United States of America. 2002 Academic Article GET IT
Times cited: 305
A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. Journal of virology. 2002 Academic Article GET IT
Times cited: 53
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. Journal of virology. 2001 Academic Article GET IT
Times cited: 706
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. Journal of virology. 2001 Academic Article GET IT
Times cited: 158
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 327
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of virology. 2001 Academic Article GET IT
Times cited: 609
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. Journal of virology. 2001 Review GET IT
Times cited: 108
HIV fusion and its inhibition. Antiviral research. 2001 Review GET IT
Times cited: 110
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology. 2001 Academic Article GET IT
Times cited: 50
HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry. AIDS research and human retroviruses. 2001 Academic Article GET IT
Times cited: 16
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of virology. 2001 Academic Article GET IT
Times cited: 227
Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. Journal of virology. 2000 Academic Article GET IT
Times cited: 59
HIV: much at stake with kidneys?. Journal of the American Society of Nephrology : JASN. 2000 Editorial Article GET IT
HIV-1 membrane fusion: targets of opportunity. The Journal of cell biology. 2000 Comment GET IT
Times cited: 245
New targets for inhibitors of HIV-1 replication. Nature reviews. Molecular cell biology. 2000 Review GET IT
Times cited: 172
The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunological reviews. 2000 Review GET IT
Times cited: 236
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. The Journal of infectious diseases. 2000 Academic Article GET IT
Times cited: 67
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. Journal of virology. 2000 Academic Article GET IT
Times cited: 157
Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. Journal of virology. 2000 Academic Article GET IT
Times cited: 96
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 423
Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology. 2000 Academic Article GET IT
Times cited: 37
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. The Journal of infectious diseases. 2000 Academic Article GET IT
Times cited: 43
Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS (London, England). 2000 Academic Article GET IT
Times cited: 69
Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection. AIDS research and human retroviruses. 2000 Academic Article GET IT
Times cited: 9
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Journal of virology. 2000 Academic Article GET IT
Times cited: 460
A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. Journal of virology. 1999 Academic Article GET IT
Times cited: 118
Viral phenotype and CCR5 genotype. Nature medicine. 1999 Letter GET IT
Times cited: 3
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (London, England). 1999 Academic Article GET IT
Times cited: 402
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. Journal of virology. 1999 Academic Article GET IT
Times cited: 164
HIV. See a pocket, block it. Nature. 1999 Comment GET IT
Times cited: 7
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. The Journal of clinical investigation. 1999 Academic Article GET IT
Times cited: 214
The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. Journal of virology. 1999 Academic Article GET IT
Times cited: 106
HIV-1 entry inhibitors: evading the issue. Nature medicine. 1999 Article GET IT
Times cited: 93
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Journal of virology. 1999 Academic Article GET IT
Times cited: 225
Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?. Journal of virology. 1999 Academic Article GET IT
Times cited: 110
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. The Journal of infectious diseases. 1999 Academic Article GET IT
Times cited: 161
HIV-1 neutralizing antibodies: how full is the bottle?. Nature medicine. 1999 Comment GET IT
Times cited: 75
HIV vaccines. Magic of the occult?. Science (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 23
Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. Journal of virology. 1999 Academic Article GET IT
Times cited: 129
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS (London, England). 1999 Review GET IT
Times cited: 274
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. Journal of virology. 1998 Academic Article GET IT
Times cited: 70
Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. Journal of virology. 1998 Academic Article GET IT
Times cited: 143
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. Journal of virology. 1998 Academic Article GET IT
Times cited: 145
Clinical trials of HIVIG. The Journal of infectious diseases. 1998 Letter GET IT
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. The Journal of experimental medicine. 1998 Academic Article GET IT
Times cited: 213
HIV. Envelope's letters boxed into shape. Nature. 1998 Comment GET IT
Times cited: 40
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. Journal of virology. 1998 Academic Article GET IT
Times cited: 279
Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS research and human retroviruses. 1998 Academic Article GET IT
Times cited: 80
Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. AIDS research and human retroviruses. 1998 Academic Article GET IT
Times cited: 47
Why do we not have an HIV vaccine and how can we make one?. Nature medicine. 1998 Academic Article GET IT
Times cited: 101
Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. Journal of virology. 1998 Academic Article GET IT
Times cited: 122
Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. Journal of virology. 1998 Academic Article GET IT
Times cited: 31
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nature medicine. 1998 Academic Article GET IT
Times cited: 359
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. Journal of virology. 1998 Academic Article GET IT
Times cited: 66
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. Journal of virology. 1998 Academic Article GET IT
Times cited: 145
Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS research and human retroviruses. 1998 Academic Article GET IT
Times cited: 51
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. Journal of virology. 1998 Academic Article GET IT
Times cited: 202
A new classification for HIV-1. Nature. 1998 Letter GET IT
Times cited: 704
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature medicine. 1998 Academic Article GET IT
Times cited: 687
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. Journal of virology. 1998 Academic Article GET IT
Times cited: 206
Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. Journal of virology. 1998 Academic Article GET IT
Times cited: 118
Neutralization assays using the BZ167 strain of human immunodeficiency virus type 1. The Journal of infectious diseases. 1997 Letter GET IT
Times cited: 2
Different subtypes of HIV-1 and cutaneous dendritic cells. Science (New York, N.Y.). 1997 Letter GET IT
Times cited: 17
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. The Journal of experimental medicine. 1997 Academic Article GET IT
Times cited: 331
Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. Journal of virology. 1997 Academic Article GET IT
Times cited: 80
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. Journal of virology. 1997 Academic Article GET IT
Times cited: 79
An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS research and human retroviruses. 1997 Academic Article GET IT
Times cited: 31
Co-receptors for HIV-1 entry. Current opinion in immunology. 1997 Review GET IT
Times cited: 455
HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS research and human retroviruses. 1997 Review GET IT
Times cited: 53
HIV-cell fusion. The viral mousetrap. Nature. 1997 Comment GET IT
Times cited: 64
Coreceptors: implications for HIV pathogenesis and therapy. Science (New York, N.Y.). 1997 Review GET IT
Times cited: 220
Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. Journal of molecular biology. 1997 Academic Article GET IT
Times cited: 50
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. Journal of virology. 1997 Academic Article GET IT
Times cited: 161
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. Journal of virology. 1997 Academic Article GET IT
Times cited: 216
Large induction of c-Myc is not essential for the mitogenic response of Swiss 3T3 fibroblasts. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 11
Demonstration of peripheral fucose units in N-linked glycans of human immunodeficiency virus type 1 gp 120: effects on glycoprotein conformation. Archives of virology. 1997 Academic Article GET IT
Times cited: 11
Determining neutralization serotypes of HIV type 1 by neural networks. AIDS research and human retroviruses. 1996 Academic Article GET IT
Times cited: 13
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996 Academic Article GET IT
Times cited: 960
The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. AIDS research and human retroviruses. 1996 Review GET IT
Times cited: 35
Chemoattractants attract HIV researchers. The Journal of experimental medicine. 1996 Comment GET IT
Times cited: 11
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996 Academic Article GET IT
Times cited: 2826
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. Journal of virology. 1996 Academic Article GET IT
Times cited: 71
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. Journal of virology. 1996 Academic Article GET IT
Times cited: 288
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of virology. 1996 Academic Article GET IT
Times cited: 1002
Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. The Journal of experimental medicine. 1996 Academic Article GET IT
Times cited: 72
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of virology. 1996 Academic Article GET IT
Times cited: 204
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of virology. 1996 Academic Article GET IT
Times cited: 144
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Journal of virology. 1995 Academic Article GET IT
Times cited: 463
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. Journal of virology. 1995 Academic Article GET IT
Times cited: 380
HIV vaccines. Back to primary school. Nature. 1995 Article GET IT
Times cited: 50
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. The Journal of experimental medicine. 1995 Academic Article GET IT
Times cited: 308
Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. Journal of immunology (Baltimore, Md. : 1950). 1995 Academic Article GET IT
Times cited: 93
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. Journal of virology. 1995 Academic Article GET IT
Times cited: 110
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. Journal of virology. 1995 Academic Article GET IT
Times cited: 25
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS (London, England). 1995 Review GET IT
Times cited: 194
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of virology. 1995 Academic Article GET IT
Times cited: 389
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. Journal of virology. 1994 Academic Article GET IT
Times cited: 111
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 181
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (New York, N.Y.). 1994 Academic Article GET IT
Times cited: 976
Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 81
Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. Journal of virology. 1994 Academic Article GET IT
Times cited: 153
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. Journal of virology. 1994 Academic Article GET IT
Times cited: 58
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 186
Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. Journal of virology. 1994 Academic Article GET IT
Times cited: 52
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of virology. 1994 Academic Article GET IT
Times cited: 417
Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS research and human retroviruses. 1994 Academic Article GET IT
Times cited: 159
Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. Journal of acquired immune deficiency syndromes. 1994 Academic Article GET IT
Times cited: 25
Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop. Journal of virology. 1994 Academic Article GET IT
Times cited: 23
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. Journal of virology. 1994 Academic Article GET IT
Times cited: 238
Antigenic variation in gp120s from molecular clones of HIV-1 LAI. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 32
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. Journal of virology. 1993 Academic Article GET IT
Times cited: 301
Detecting SIV gp120 and its interaction with soluble CD4 by ELISA. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 6
Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 43
The role of CD4 in HIV binding and entry. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 1993 Review GET IT
Times cited: 85
Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 1993 Academic Article GET IT
Times cited: 8
Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. Journal of virology. 1993 Academic Article GET IT
Times cited: 107
Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. Journal of virology. 1993 Academic Article GET IT
Times cited: 124
A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 16
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. Journal of virology. 1993 Academic Article GET IT
Times cited: 563
A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1. Journal of virology. 1993 Academic Article GET IT
Times cited: 17
Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 74
The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 33
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. Journal of virology. 1993 Academic Article GET IT
Times cited: 191
Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 33
Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. AIDS research and human retroviruses. 1993 Academic Article GET IT
Times cited: 27
Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins?. AIDS research and human retroviruses. 1992 Academic Article GET IT
Times cited: 81
HIV-negative AIDS. Lancet (London, England). 1992 Conference Paper GET IT
Times cited: 13
A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. Journal of virology. 1992 Academic Article GET IT
Times cited: 116
Antigenicity of the HIV-2 V3 loop. AIDS (London, England). 1992 Letter GET IT
Times cited: 1
Complementation of human immunodeficiency virus glycoprotein mutations in trans. The Journal of general virology. 1992 Academic Article GET IT
Times cited: 9
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology. 1992 Academic Article GET IT
Times cited: 276
CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro. Virology. 1992 Academic Article GET IT
Times cited: 13
Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. AIDS research and human retroviruses. 1992 Academic Article GET IT
Times cited: 28
Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. AIDS research and human retroviruses. 1992 Academic Article GET IT
Times cited: 43
Kinetics of the HIV-CD4 interactions and virus-cell fusion. AIDS (London, England). 1992 Editorial Article GET IT
Times cited: 7
Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS research and human retroviruses. 1992 Academic Article GET IT
Times cited: 171
Twin-Site ELISAs for fos and myc Oncoproteins Using the AMPAK System. Methods in molecular biology (Clifton, N.J.). 1992 Academic Article GET IT
Twin-Site ELISAs for fos and myc Oncoproteins Using the AMPAK System. Methods in molecular biology (Clifton, N.J.). 1992 Academic Article GET IT
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Journal of virology. 1992 Academic Article GET IT
Times cited: 257
Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology. 1991 Academic Article GET IT
Times cited: 42
AIDS. Passive primate protection. Nature. 1991 Comment GET IT
Times cited: 6
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. The Journal of experimental medicine. 1991 Academic Article GET IT
Times cited: 520
Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science (New York, N.Y.). 1991 Letter GET IT
Times cited: 47
c-myc protein expression in untransformed fibroblasts. Oncogene. 1991 Academic Article GET IT
Times cited: 143
Immunological incompetence in AIDS. AIDS (London, England). 1991 Letter GET IT
Times cited: 4
Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. Journal of virology. 1991 Academic Article GET IT
Times cited: 130
HIV infectivity. Nature. 1991 Letter GET IT
Times cited: 12
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. Journal of virology. 1991 Academic Article GET IT
Times cited: 189
Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. Virology. 1991 Academic Article GET IT
Times cited: 22
Binding of recombinant HIV-1 and HIV-2 SU glycoproteins to sCD4. Journal of acquired immune deficiency syndromes. 1991 Letter GET IT
Times cited: 9
Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 7
Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant. Journal of virology. 1991 Academic Article GET IT
Times cited: 44
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?. AIDS research and human retroviruses. 1991 Academic Article GET IT
Times cited: 200
The role of the V3 loop of gp120 in HIV infection. AIDS (London, England). 1991 Review GET IT
Times cited: 139
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (New York, N.Y.). 1990 Academic Article GET IT
Times cited: 469
Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies. AIDS research and human retroviruses. 1990 Academic Article GET IT
Times cited: 17
GTP gamma S inhibits early c-myc protein accumulation but not DNA synthesis in Swiss 3T3 fibroblasts. FEBS letters. 1990 Academic Article GET IT
Times cited: 3
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. The Journal of experimental medicine. 1990 Academic Article GET IT
Times cited: 173
HIV-1 envelope protein gp120 expression by secretion in E. coli: assessment of CD4 binding and use in epitope mapping. Journal of virological methods. 1990 Academic Article GET IT
Times cited: 16
Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. AIDS research and human retroviruses. 1990 Academic Article GET IT
Times cited: 51
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (London, England). 1990 Academic Article GET IT
Times cited: 101
Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS (London, England). 1990 Academic Article GET IT
Times cited: 119
Protein kinase C-induced stimulation or inhibition of cellular proliferation in a murine macrophage tumor cell line. Cancer research. 1990 Academic Article GET IT
Times cited: 4
Selection and preliminary characterization of variant lines of a murine macrophage tumor resistant to the antiproliferative effects of phorbol esters. Cancer research. 1990 Academic Article GET IT
Mitogen-stimulated activation of the Na+/H+ antiporter does not regulate S6 phosphorylation or protein synthesis in murine thymocytes or Swiss 3T3 fibroblasts. The Journal of biological chemistry. 1990 Academic Article GET IT
Times cited: 6
Induction of c-fos protein by activation of vasopressin receptors in smooth muscle cells. FEBS letters. 1989 Academic Article GET IT
Times cited: 13
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (London, England). 1989 Academic Article GET IT
Times cited: 55
Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS research and human retroviruses. 1988 Academic Article GET IT
Times cited: 62
Ca2+ and pH responses to sequential additions of mitogens in single 3T3 fibroblasts: correlations with DNA synthesis. The Journal of biological chemistry. 1988 Academic Article GET IT
Times cited: 39
C-fos gene activation in murine thymocytes by a mechanism independent of protein kinase C or a Ca2+ signal. FEBS letters. 1988 Academic Article GET IT
Times cited: 3
A sensitive enzyme-linked immunosorbence assay for the c-fos and v-fos oncoproteins. Biochimica et biophysica acta. 1988 Academic Article GET IT
Times cited: 4
Synergistic signals in the mechanism of antigen-induced exocytosis in 2H3 cells: evidence for an unidentified signal required for histamine release. The Journal of cell biology. 1987 Academic Article GET IT
Times cited: 69
Extraction and recovery of inositol phosphates from tissues. The Biochemical journal. 1987 Letter GET IT
Times cited: 63
Calcium regulates inositol 1,3,4,5-tetrakisphosphate production in lysed thymocytes and in intact cells stimulated with concanavalin A. The EMBO journal. 1987 Academic Article GET IT
Times cited: 32
The early mitogenic pathway in mouse thymocytes: an analysis of the dual signal hypothesis. Advances in experimental medicine and biology. 1987 Academic Article GET IT
Times cited: 1
Calcium and cell proliferation. British medical bulletin. 1986 Review GET IT
Times cited: 71
c-fos and c-myc gene activation, ionic signals, and DNA synthesis in thymocytes. The Journal of biological chemistry. 1986 Academic Article GET IT
Times cited: 66
A common sequence of calcium and pH signals in the mitogenic stimulation of eukaryotic cells. Nature. 1985 Academic Article GET IT
Times cited: 281
Early response pattern analysis of the mitogenic pathway in lymphocytes and fibroblasts. Journal of cell science. Supplement. 1985 Review GET IT
Times cited: 26
Mitogens increase phosphorylation of phosphoinositides in thymocytes. Nature. 1984 Academic Article GET IT
Times cited: 131
Calcium signals and phospholipid methylation in eukaryotic cells. The Biochemical journal. 1984 Academic Article GET IT
Times cited: 26
The calcium signal and phosphatidylinositol breakdown in 2H3 cells. The Journal of biological chemistry. 1984 Academic Article GET IT
Times cited: 154
The mechanism of the calcium signal and correlation with histamine release in 2H3 cells. The Journal of biological chemistry. 1984 Academic Article GET IT
Times cited: 271
Large effects of preparative techniques on lymphocyte cyclic AMP content. The Biochemical journal. 1983 Academic Article GET IT
Times cited: 8
The bivalent-cation dependence of phosphatidylinositol synthesis in a cell-free system from lymphocytes. The Biochemical journal. 1983 Academic Article GET IT
Times cited: 3
Free cytoplasmic calcium concentration and the mitogenic stimulation of lymphocytes. The Journal of biological chemistry. 1983 Academic Article GET IT
Times cited: 327
Early increases in phospholipid methylation are not necessary for the mitogenic stimulation of lymphocytes. The Journal of biological chemistry. 1982 Academic Article GET IT
Times cited: 20

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Neutralization of primary HIV-1 viruses awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2023 - 2028
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2020 - 2025
Neutralization of Primate Immunodeficiency Viruses awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2018 - 2023
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2021 - 2022

Design HIV Trimer Immunogens to Elicit bNAbs Aimed at two Epitopes awarded by Bill & Melinda Gates Foundation Principal Investigator Subaward 2019 - 2023
Phase 1 clinical study testing GT1.1 trimer awarded by Bill & Melinda Gates Foundation Principal Investigator Subaward 2019 - 2023

more ...

less ...

Background

education and training

Ph.D., Cambridge University (United Kingdom) 1982
M.A., Cambridge University (United Kingdom) 1981
B.A., Downing College (United Kingdom) 1978

Contact

full name

John P Moore

primary email

jpm2003@med.cornell.edu

VIVO Weill Cornell Medical College

John P Moore Professor of Microbiology and Immunology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email